Document is current

Article History

Received: 3 October 2025

Accepted: 16 March 2026

First Online: 25 March 2026

Declarations

:

: The IPF-PRO Registry was approved by the Duke University Institutional Review Board (Pro00046131). The protocol was approved by the relevant Institutional Review Boards and/or local Independent Ethics Committees prior to enrollment at each site (see Acknowledgments). Ethics approval was granted by the Duke Institutional Review Board Protocol Number Pro00082241 to use the biosamples obtained as part of the IPF-PRO Registry for these analyses. The study was carried out in compliance with the principles of the Declaration of Helsinki and the Harmonized Tripartite Guideline for Good Clinical Practice of the International Conference on Harmonization. All patients provided written informed consent. The IPF-PRO Registry was registered with ClinicalTrials.gov (Identifier: NCT01915511).

: Not applicable.

: ACS, MLN, SMP and JLT are faculty members, and HM is a staff member, at the Duke Clinical Research Institute, which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc. to coordinate the IPF-PRO/ILD-PRO Registry. JLT also reports grants from AstraZeneca, Boehringer Ingelheim, CareDx and has participated on Data Safety Monitoring Boards or Advisory Boards for Altavant, Avalyn, Natera, Sanofi, Theravance. SMP also reports research funding to Duke University/Duke Clinical Research Institute from Bristol Myers Squibb; royalties or licenses from UpToDate; and consulting fees from Bristol Myers Squibb, Mallinckrodt, Sanofi. RS and NMP are employees of Boehringer Ingelheim. JAB is a site investigator for the IPF-PRO/ILD-PRO Registry.